Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting
AbstractPurpose of review
A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway.Recent findings
Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer.Summary
Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients’ selection will be the goal of future research.